Pathology gap fees could increase if Healius takeover proceeds: ACCC
The competition watchdog has published a 30-page Statement of Issues regarding a proposed takeover of Healius Pathology.
The competition watchdog has warned that a proposed merger of Australian Clinical Labs and Healius Pathology could increase private billing, blow out turnaround times and financially punish GP practices.
The ACCC is analysing a $1.6 billion takeover bid from Australian Clinical Labs (ACL) — which the Healius board opposes — and has now released a Statement of Issues running to 30 pages.
